Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Vir Biotechnology, Inc. | Director | Common Stock | 1.31M | $16.4M | $12.52 | Jan 8, 2025 | Direct |
Denali Therapeutics Inc. | Director | Common Stock | 108K | $2.26M | $20.91 | Jan 2, 2025 | Direct |
Allogene Therapeutics, Inc. | Director | Stock Option (Right to buy) | 95.5K | $919K | $9.62 | Jun 5, 2024 | Direct |
Allogene Therapeutics, Inc. | Director | Common Stock | 163K | $380K | $2.34 | Jun 5, 2024 | Direct |
Vir Biotechnology, Inc. | Director | Stock Option (Right to Buy) | 16K | $24.5K | $1.53 | May 30, 2024 | Direct |
Denali Therapeutics Inc. | Director | Stock Option (right to buy) | 17.9K | May 31, 2024 | Direct | ||
Akouos, Inc. | Director | Stock Option (right to buy) | 0 | Dec 1, 2022 | Direct |